Abstract
Over the last few years, an international consensus has been reached for the treatment of chronic neuropathic pain. On the basis of randomized clinical trials, medications recommended for neuropathic pain include antidepressants (tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine), calcium channel alpha 2-delta ligands (i.e., gabapentin and pregabalin), topical lidocaine and opioids. The recommendations for clinical practice proposed by the French Society of Pain include a therapeutic algorithm and criteria for referral patient to a pain clinic by general practitioners. Current therapeutic perspectives include the development of drugs acting on novel targets as well as the pharmacological prevention of postoperative neuropathic pain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
